A Study Looking Back at Uveal Melanoma Patients to Learn What Works Best

In Plain English

This is not a trial where you receive a new treatment. Instead, researchers at the Medical University of Vienna are creating a detailed record of patients with uveal melanoma who were treated there between 1997 and 2021. They're reviewing old medical charts and collecting information about what treatments patients received, how long they survived, and how their disease progressed over time. Why does this matter? Uveal melanoma is rare, which makes it hard for doctors to study. By carefully analyzing the medical records of many patients treated over 25 years, researchers can spot patterns about which treatments worked better, which patients did better or worse, and what factors matter most. This information helps doctors make better decisions for future patients like you. If you're eligible, your participation means allowing researchers to review your medical records and add your information (kept completely private) to their database. There are no new treatments to try, no extra appointments, and no additional procedures. You're simply helping doctors learn from your care to help others in the future.

What This Trial Does

Background: Uveal melanoma (UM) is a common primary ocular malignancy associated with limited overall survival in the advanced stage of the disease. Fundamental breakthrough regarding the management of the disease and the overall-survival have not yet been achieved. Studies with large cohorts are difficult to perform due to limited patient numbers, therefore retrospective analyses are of great potential to gain further knowledge in a disease with high clinical needs. Aim: The proposed project is a register for patients with UM treated at the Department of Ophthalmology and Optometry at the Medical University of Vienna between 01.01.1997 and 31.12.2021. Patients and Methods: Patients treated for UM at the Department of Ophthalmology and Optometry at the Medical University of Vienna between 01.01.1997 and 31.12.2021 will be included in the register. Information on the baseline characteristics, survival times and course of the disease will be gathered via retrospective chart review and saved in a password-secured database.

Who Can Join

Treatments